Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.69 |
| ▸ | SRC | P12931 | 4/20 | 0.69 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | FYN | P06241 | 1/20 | 0.69 |
| ▸ | YES1 | P07947 | 1/20 | 0.69 |
| ▸ | LYN | P07948 | 1/20 | 0.69 |
| ▸ | HCK | P08631 | 1/20 | 0.69 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 1/20 | 0.69 |
| ▸ | PRKACA | P17612 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061476 | 1.00 | EGFR (0.69) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4071514 | 1.00 | EGFR (0.69) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4071523 | 0.90 | EGFR (0.56) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4064546 | 0.89 | EGFR (0.54) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4068048 | 0.88 | EGFR (0.52) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4061778 | 0.87 | EGFR (0.54) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4066483 | 0.87 | EGFR (0.52) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4064966 | 0.87 | EGFR (0.53) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4065659 | 0.85 | EGFR (0.52) | EGFRSRCTNK2DYRK1ARET | |
| SCHEMBL4066587 | 0.85 | EGFR (0.52) | EGFRSRCTNK2DYRK1ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863792-B1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | ERBB2, ERBB4, EGFR | EGFR 3/4885SRC 57/4885TNK2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.